On the one hand, inhibiting PRMT5 activity can promote cell cycle arrest and the apoptosis of tumor cells, reducing its metastatic capability [10–12]; on the other hand, it can restore the expression of tumor suppressor genes such as ST7 and PTEN in gliomas. This evidence concerns the gene PRMT5 and central nervous system cancer.